Toronto neurologist Dr. Galit Kleiner is pioneering experimental research at Baycrest hospital to treat paratonia, a common yet often unrecognized movement disorder in advanced dementia patients. This condition causes involuntary muscle stiffness and pain, frequently mistaken for aggression. Kleiner's work focuses on using botulinum toxin (BoNT-A), a drug already approved for other neurological conditions, to alleviate these symptoms. Initial trials have shown significant success, easing pain and improving mobility for patients, allowing for better care and increased physical connection between patients and families. Despite promising results published in the Journal of the American Medical Directors Association, larger trials are needed, but funding and Health Canada's approval for paratonia remain obstacles.